Ritonavir News and Research

RSS

Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Rebounding of COVID-19 symptoms and viral load are common among untreated COVID-19 patients

Researchers characterize COVID-19 symptom and viral load rebounds among untreated individuals with mild-to-moderate SARS-CoV-2 infection.

27 Feb 2023

Two newer simplified HIV treatment options found to be at least as effective as the standard of care

Two newer simplified treatment options are at least as effective as current approaches, according to the results of a world-first international clinical trial into second-line HIV therapy led by the Kirby Institute at UNSW Sydney and presented today at the Conference on Retroviruses and Opportunistic Infections in Seattle.

23 Feb 2023

Research reports full efficacy of Sotrovimab against BQ.1.1 viral replication in a non-human primate challenge model

Researchers used a non-human primate model to show that Sotrovimab, a commercial mAb also known as Xevudy, was fully effective against SARS-CoV-2 Omicron BA.5 sub-lineage and its derivatives, such as BQ.1.1.

17 Feb 2023

Nirmatrelvir–ritonavir found to lower COVID-19 severity outcomes

Researchers evaluated the effectiveness of nirmatrelvir–ritonavir in preventing coronavirus disease 2019 (COVID-19) severity outcomes during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant predominance.

16 Feb 2023

Cohort study examines the incidence of SARS-CoV-2 rebound in patients on oral antivirals

Researchers performed a retrospective population-wide cohort study using anonymized data in Hong Kong, China, between February 26 and July 3, 2022.

16 Feb 2023

Nirmatrelvir-ritonavir therapy effective against Omicron BA.4/BA.5

Researchers examine non-hospitalized adult patients with COVID-19 treated with nirmatrelvir-ritonavir.

15 Feb 2023

New insights into the role of T-cells during long COVID

Researchers characterize the trajectory of long COVID in patients eight months after recovering from infection.

14 Feb 2023

Paxlovid can prevent hospitalization and death for patients infected with Omicron variants, study shows

Though many Coloradans are proceeding as though the COVID-19 pandemic is over, the virus continues to circulate, evolve and have an impact-;especially for older adults and those with underlying medical conditions.

13 Feb 2023

What older Americans need to know about taking Paxlovid

A new coronavirus variant is circulating, the most transmissible one yet. Hospitalizations of infected patients are rising. And older adults represent nearly 90% of U.S. deaths from covid-19 in recent months, the largest portion since the start of the pandemic.

18 Jan 2023

New research on nirmatrelvir resistance in SARS-CoV-2 using powerful replicon cell culture systems

In a recent study posted to the bioRxiv* preprint server, researchers at Emory University used severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Washington (WA.1) and Omicron (BA.1) strains to test for mutations that could result in resistance to the antiviral drug nirmatrelvir.

8 Jan 2023

Phase III trial shows noninferiority of VV116 compared to nirmatrelvir–ritonavir among adults with mild-to-moderate COVID-19 at risk of progression

Researchers presented the results of a phase III randomized controlled trial of oral SARS-CoV-2 antiviral VV116.

3 Jan 2023

What are the long-term outcomes of critical COVID-19 patients?

Researchers assessed the long-term outcomes of critically ill coronavirus disease 2019 (COVID-19) patients.

21 Dec 2022

Does nirmatrelvir and ritonavir reduce the risk of hospitalization or death among outpatients with early COVID-19?

Researchers investigated the efficacy of ritonavir and nirmatrelvir combination treatment in reducing the risk of COVID-19 severity outcomes such as hospital admissions and deaths when administered during the initial period of SARS-CoV-2 infections.

16 Dec 2022

Study finds bebtelovimab therapy lacks efficacy in patients infected with SARS-CoV-2 Omicron subvariants

Researchers assessed the impact of bebtelovimab (BEB) monoclonal antibody in the treatment of high-risk SARS-CoV-2 Omicron variant-infected patients.

13 Dec 2022

The effectiveness of nirmatrelvir-ritonavir and molnupiravir for the treatment of COVID-19 among US veterans

Researchers evaluated the effectiveness of SARS-CoV-2 antivirals, nirmatrelvir-ritonavir, and molnupiravir among Veterans in the United States of America.

13 Dec 2022

What is the incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir?

Researchers evaluated the incidence of COVID-19 rebound among SARS-CoV-2 -positive patients treated with oral antiviral drugs such as nirmatrelvir-ritonavir combination and molnupiravir.

12 Dec 2022

Exploring clinical characteristics and outcomes of hospitalized COVID-19 patients

Researchers described the clinical characteristics and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19) in the Netherlands.

24 Nov 2022

What is the prevalence of contraindications to Paxlovid among hospitalized COVID-19 patients?

Researchers examined the prevalence of contraindications to nirmatrelvir-ritonavir (Paxlovid) in hospitalized coronavirus disease 2019 (COVID-19) patients.

17 Nov 2022

Among US veterans with COVID-19, few used antivirals or monoclonal antibodies

In a recent study published in the journal JAMA Network, researchers in the United States investigated factors that restricted the use of antivirals directed at severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States (US) between January and February 2022.

16 Nov 2022

Short-term outcomes in pregnant patients with COVID-19 who received nirmatrelvir–ritonavir treatment

Researchers investigated the short-term outcomes of treating pregnant patients exhibiting mild to moderate symptoms of COVID-19 with Paxlovid, which is a combination of the antivirals nirmatrelvir and ritonavir.

15 Nov 2022